Chugai Pharmaceutical

An objective of the present invention is to provide stable antibody-containing formulations which are suitable for subcutaneous administration and in which aggregation formation is suppressed during long-term storage.The present inventors discovered that a significant stabilization effect was achieved by using an acidic amino acid, aspartic acid or glutamic acid as a counter ion species in histidine buffer or tris(hydroxymethyl)aminomethane, specifically by using histidine-aspartate buffer or histidine-glutamate buffer, or tris(hydroxymethyl)aminomethane-aspartate or tris(hydroxymethyl)aminomethane-glutamate as a buffer. The present inventors also discovered that a significant stabilization effect was achieved by using an acidic amino acid, aspartic acid or glutamic acid, as a counter ion species to a basic amino acid such as arginine, specifically by using arginine-aspartate or arginine-glutamate.

The present disclosure provides anti-CTLA-4 antibodies and methods of producing and using the antibodies. The present disclosure also provides nucleic acids encoding the anti-CTLA-4 antibodies and host cells containing the nucleic acids. Furthermore, the present disclosure provides polypeptides containing a variant Fc region and methods of producing and using the polypeptides.

The disclosure provides anti-myostatin antibodies and methods of making and using the same. Nucleic acids encoding the anti-myostatin antibodies and host cells comprising the nucleic acids are also provided. The disclosure also provides polypeptides containing a variant Fc region and methods of making and using the same. Nucleic acids encoding the polypeptides and host cells comprising the nucleic acids are also provided.

Provided are a perfusion culture method and the like that are able to improve the productivity in the production of recombinant protein. Specifically, a method for improving recombinant protein production in perfusion culture of an animal cell having a capacity to produce a recombinant protein, the method comprising adding cystine and/or ammonium iron citrate to a cell culture medium, and the like, are provided.

The disclosure provides anti-DENV antibodies and methods of making and using the same. Nucleic acids encoding anti- DENV antibodies and host cells comprising the nucleic acids are also provided. The anti-DENV antibodies have uses that include treating DENV infection. The disclosure also provided polypeptides containing a variant Fc region and methods of making the same. Nucleic acids encoding polypeptides and host cells comprising the nucleic acids are also provided. The polypeptides have uses that include treating a viral infection. Also claimed is a polypeptide comprising a Fc variant comprising at least one amino acid alteration in a parent Fc region, wherein the variant Fc region has a substantially decreased FcYR-binding activity and does not have a substantially decreased C1 q-binding activity when compared to the parent Fc region.

The present invention relates to a MEK-inhibiting agent comprising as an active ingredient a compound represented by general formula (1) below or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or salt: <img class="EMIRef" id="7daffbbd-4fef-4755-83f0-674c51246527-ia01" /> wherein: ring A is a group represented by general formula (2), (3) or (4) below (where the bonds denoted by *, ** and *** are bonded to -NH-, -CONH- and -CH<2>-, respectively): <img class="EMIRef" id="7daffbbd-4fef-4755-83f0-674c51246527-ia02" /> X<1>, X<2>, X<3>, X<4> and X<5> are each independently -CR<2>= or -N=; R<2> is a hydrogen atom, a halogen atom, or a Cl-4 alkyl group; R<1> is -S(=O)<2>-NH-R<8> or -S(=O)<2>-R<8>; R<8> is a C1-4 alkyl group (the C1-4 alkyl group being optionally substituted with a halogen atom, a hydroxy group, a C1-4 alkoxy group, a C3-6 cycloalkyl group or a C3-6 heterocycloalkyl group) or a C3-6 cycloalkyl group (the C3-6 cycloalkyl group being optional substituted with a C1-4 alkyl group); R<3> is a hydrogen atom, a C3-6 cycloalkyl group, or a C1-6 alkoxy group; R<5> is a halogen atom; R<6> is a hydrogen atom and R<4> is a halogen atom or a C3-6 cycloalkyl group; R<7> is a C1-4 alkyl group; and R<9> is a hydrogen atom.

Zusammenfassung wird geladen …

Zusammenfassung wird geladen …

Zusammenfassung wird geladen …

Zusammenfassung wird geladen …